Table 4 BWC0977 is superior to gepotidacin against sensitive and multidrug-resistant (MDR) bacterial strains

From: Structural interactions of BWC0977 with Klebsiella pneumoniae topoisomerase IV and biochemical basis of its broad-spectrum activity

Bacterial strains

MIC (μg/ml)

BWC0977

Gepotidacin

Ciprofloxacin

K. pneumoniae ATCC 13883

0.06

1

0.06

S. aureus ATCC 29213

0.007

0.125

1

E. coli ATCC 25922

0.060

0.5

0.007

A. baumannii ATCC 19606

0.125

2

0.5

E. faecalis ATCC 29212

0.03

1

0.5

P. aeruginosa ATCC 27853

0.125

1

0.06

E. coli BAA 2471

0.5

2

>4

E. coli BAA 2469

0.01

0.5

>4

K. pneumoniae BAA 2782

0.125

1

>4

K. pneumoniae BAA 2784

0.125

1

>4

A. baumannii BAA 2885

0.5

2

>4

K. pneumoniae KPNIH1

1

8

>4

P. aeruginosa BAA 2794

0.125

0.5

>4

P. aeruginosa BAA 2797

0.25

1

>4

  1. The minimum inhibitory concentrations of BWC0977 compared with gepotidacin and ciprofloxacin against drug-sensitive and multidrug-resistant (MDR) strains from ATCC. Values represent the mean of two independent experiments. E. coli BAA 2471, E. coli BAA 2469, K. pneumoniae BAA 2782, K. pneumoniae KPNIH1, P. aeruginosa BAA 2794, and P. aeruginosa BAA 2797 are resistant to ciprofloxacin and meropenem. K. pneumoniae BAA 2784 and A. baumannii BAA 2885 are resistant to ciprofloxacin, meropenem, and colistin.
Back to article page